Vaxxinity, Inc.: auditor change — Vaxxinity auditor Armanino resigns; appoints Peter Powchik as EVP Global Scientific Director

Vaxxinity, Inc.

Armanino LLP resigns as auditor effective upon new appointment or Q3 2023 filing; cites transition away from public company audits.
No disagreements or reportable events in past two fiscal years and subsequent interim period.
Company warns inability to timely replace auditor could impair SEC filings, capital raising, and investor confidence.
Peter Powchik, M.D. appointed EVP, Global Scientific Director effective Oct 1, 2023; previously led development of seven approved drugs at Regeneron.
Ulo Palm transitions from CMO to senior advisor effective Oct 1, 2023; oversaw Phase 3 COVID-19 and Phase 1 Parkinson's trials.

item 4.01 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 1.0

Armanino LLP resigned as auditor of Vaxxinity, Inc..

Action: resignation
Auditor: Armanino LLP

Exact text from the filing

(the “Company”) was informed by Armanino LLP (“Armanino”) that it intends to resign as the Company’s independent registered public accounting firm, effective upon the earlier of (i) filing of the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2023 and (ii) the Company’s appointment of a new independent registered public accounting firm. The audit committee of the Company’s board of directors accepted but did not request or recommend Armanino’s resignation. Armanino advised the Company that its decision was due to Armanino’s transition away from providing financial statement audit services to public companies.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001562762-23-000295

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.